Abstracts & publications

LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity

There is a world beyond αvβ3: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8,αvβ3 and α5β1 by positron emission tomography

Preclinical development and characterisation of 99mTc-NM-01 for SPECT/CT imaging of human PD-L1

European Molecular Imaging Meeting 2021 – 68-Trivehexin enables PET/CT imaging of carcinomas in humans by targeting the “cancer integrin” αvβ6

European Molecular Imaging Meeting 2021 – Peptide trimers as complex systems: Optimization of pharmacokinetics by simple phenylalanine-tyrosine exchange

PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin” αvβ6

PSA-targeted Alpha-, Beta-, and Positron emitting immunotheranostics in murine prostate cancer models and non human primates

Radiotheranostic targeting of fPSA

Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Why next generation radiopharmaceuticals will play a key role in the quest for precision medicine

Open Access Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer

99mTc-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression